dQM QICore Content Implementation Guide
2025.0.0 - CI Build
dQM QICore Content Implementation Guide, published by cqframework. This guide is not an authorized publication; it is the continuous build for version 2025.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/dqm-content-qicore-2025/ and changes regularly. See the Directory of published versions
Official URL: https://madie.cms.gov/Measure/CMS646FHIRIntravesicalBCGTherapy | Version: 1.0.000 | |||
Active as of 2025-08-22 | Responsible: Oregon Urology | Computable Name: CMS646FHIRIntravesicalBCGTherapy | ||
Other Identifiers: Short Name: CMS646FHIR (use: usual, ), UUID:907ead5a-2f8f-468e-b774-309ea8aa6182 (use: official, ), UUID:67c8554c-9288-4de2-b8dc-45ae4673e032 (use: official, ), Publisher: 646FHIR (use: official, ) | ||||
Copyright/Legal: Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Oregon Urology Institute (OUI) and Large Urology Group Practice Association (LUGPA) disclaim all liability for the use or accuracy of third-party codes contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2004-2024. American Medical Association. LOINC(R) copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024 International Health Terminology Standards Development Organisation. ICD-10 copyright 2024 World Health Organization. All Rights Reserved. |
Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging
Metadata | |
---|---|
Title | Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder CancerFHIR |
Version | 1.0.000 |
Short Name | CMS646FHIR |
GUID (Version Independent) | urn:uuid:907ead5a-2f8f-468e-b774-309ea8aa6182 |
GUID (Version Specific) | urn:uuid:67c8554c-9288-4de2-b8dc-45ae4673e032 |
CMS Identifier | 646FHIR |
Effective Period | 2026-01-01 through 2026-12-31 |
Steward (Publisher) | Oregon Urology |
Developer | Oregon Urology |
Description | Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging |
Copyright | Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Oregon Urology Institute (OUI) and Large Urology Group Practice Association (LUGPA) disclaim all liability for the use or accuracy of third-party codes contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2004-2024. American Medical Association. LOINC(R) copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024 International Health Terminology Standards Development Organisation. ICD-10 copyright 2024 World Health Organization. All Rights Reserved. |
Disclaimer | The performance measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by TM or [TM]. |
Rationale | Bladder cancer is ranked 10th for new cancer cases in 2020 and is the ninth leading cause of cancer death in the United States. There are 81,400 estimated new cases in 2020 and 17,980 estimated deaths in 2020. In 2016, an estimated 699,450 people were living with bladder cancer in the United States. Early detection (discovery of cancer in situ or localized to the primary site) is found in 85% of the patients, and with these there is a five-year survival rate of 95.8% for In Situ and 69.2% for Localized. Bladder cancer is rarely found in patients under age 20, with the median age of diagnosis being 73 (NIH, 2020). National Comprehensive Cancer Network (NCCN) Guidelines for Bladder Cancer (version 6.2021) defines intravesical BCG as Category 1 Treatment for T1, Tis and Ta - high grade, non-muscle invasive bladder cancer. Most public data reflects prophylactic or adjuvant use of intravesical therapy to prevent recurrence or delay progression to a higher grade or stage. BCG has been shown to be effective as prophylaxis to prevent bladder cancer recurrences following TURBT. The NCCN Bladder Cancer Panel Members recommend BCG as the preferred option over Mitomycin C for adjuvant treatment of high-grade lesions (Ta). BCG is also standard therapy for Primary Tis. Most T1 lesions are high-risk and are similarly treated with adjuvant intravesical therapy, with BCG being a Category 1 recommendation (NCCN, 2021). |
Clinical Recommendation Statement | Intravesical BCG should be administered within 6 months of the initial diagnosis of non-muscle invasive bladder cancer. It may be administered 3-4 weeks after resection, but there needs to be pathological tumor confirmation and must be withheld if there is traumatic catheterization, bacteriuria, persistent gross hematuria, persistent severe local symptoms or systemic symptoms. The normal induction course is 6 weekly instillations of intravesical BCG (AUA Non-Muscle Invasive Bladder Cancer and American Urological Association (AUA) Guideline for the Management of Non-muscle Invasive Bladder Cancer: Stages T1, TIS, and Ta High Risk). |
Citation |
Chamie, K., Saigal, C.S., Lai, J., Hanley, J.M., Setodji, C.M., Konety, B.R., ... Urologic Diseases in America Project (2011). Compliance with Guidelines for Patients with Bladder Cancer: Variation in the Delivery of Care. Cancer.2011 Dec 1: 117(23): 5392-5401. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206145/ |
Citation |
Chang, S.S., Boorjian, S.A., Chou, R., Clark, P.E., Daneshmand, S., Konety, B.R., ... Mckiernan, J. M., (2016) American Urological Association. Non-Muscle Invasive Bladder Cancer. https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline |
Citation |
Hall, M.C., Chang, S.S., Dalbagni, G., Pruthi, R.S., Schellhammer, P.F., Seigne, J.D., ... Wolf, S., (2016). American Urological Association. Guideline for the Management of Non-muscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): Update 2016. https://www.auajournals.org/doi/10.1016/j.juro.2007.09.003 |
Citation |
Kassouf, W., Black, P., (2016) Treatment of primary non-muscle invasive urothelial bladder cancer. Literature review current through Dec. 2016. https://www.uptodate.com/contents/treatment-of-primary-non-muscle-invasive-urothelial-bladder-cancer?source=search_result&search=Treatment%20of%20primary%20non-muscle%20invasive%20urothelial%20bladder%20cancer&selectedTitle=1~150 T of primary |
Citation |
National Cancer Institute. (2020). SEER Cancer Stat Facts: Bladder Cancer. Surveillance, Epidemiology, and End Results Program. U.S. Department of Health and Human Services, National Institutes of Health. https://seer.cancer.gov/statfacts/html/urinb.html |
Citation |
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). (2021). Bladder Cancer. Version 6.2021. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf |
Citation |
Pacific Northwest Evidence-based Practice Center, Oregon Health & Science University. (2016). PCORI Topic Brief. Comparative Effectiveness of Treatments for Non-Muscle-Invasive Bladder Cancer http://www.pcori.org/sites/default/files/PCORI-Assessment-Options-Advisory-Panel-Fall-2016-Topic-Brief-Non-Muscle-Invasive-Bladder-Cancer.pdf |
Definition | Bacillus Calmette-Guerin (BCG) : A live attenuated strain of Mycobacterium bovis, first indicated as a tuberculosis vaccine, has had widespread use in intravesical immunotherapy since the 1970s |
Definition | Histology: Urothelial carcinoma |
Definition | Intravesical: Within the urinary bladder |
Definition | Primary Tumor (T) Stage - T1: The tumor invades subepithelial connective tissue (high grade or low grade) |
Definition | Primary Tumor (T) Stage - Ta: Noninvasive and high grade |
Definition | Primary Tumor (T) Stage - Tis: Carcinoma in situ: "flat tumor" |
Definition | Tumor Location: Urinary bladder |
Guidance (Usage) | Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines. The BCG dose can be full or partial and can be from any lot or manufacturer. This eCQM is a patient-based measure. Telehealth encounters are not eligible for this measure because the measure requires a clinical action that cannot be conducted via telehealth. This FHIR-based measure has been derived from the QDM-based measure CMS646v6. Please refer to the HL7 QI-Core Implementation Guide (https://hl7.org/fhir/us/qicore/STU6/) for more information on QI-Core and mapping recommendations from QDM to QI-Core STU 6 (https://hl7.org/fhir/us/qicore/STU6/qdm-to-qicore.html). |
Measure Group (Rate) (ID: Group_1) | |
Basis | boolean |
Scoring | [http://terminology.hl7.org/CodeSystem/measure-scoring#proportion: 'Proportion'] |
Type | [http://terminology.hl7.org/CodeSystem/measure-type#process: 'Process'] |
Improvement Notation | [http://terminology.hl7.org/CodeSystem/measure-improvement-notation#increase: 'Increased score indicates improvement'] |
Initial Population |
ID: InitialPopulation_1
Description: All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer with bladder cancer staging within 6 months before to 6 months after the start of the measurement period and a qualified encounter in the measurement period Logic Definition: Initial Population |
Denominator |
ID: Denominator_1
Description: Equals Initial Population Logic Definition: Denominator |
Denominator Exclusion |
ID: DenominatorExclusion_1
Description: Immunosuppressed patients, includes HIV and immunocompromised state, with a diagnosis prior to Bladder Cancer Staging. Immunosuppressive drug therapy starting on or before Bladder Cancer Staging. Active Tuberculosis diagnosis during the Bladder Cancer Staging. Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease prior to Bladder Cancer Staging. Patients who undergo cystectomy, chemotherapy or radiation within 6 months prior to Bladder Cancer Staging. Logic Definition: Denominator Exclusion |
Numerator |
ID: Numerator_1
Description: Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series: BCG is initiated within 6 months of the bladder cancer staging Logic Definition: Numerator |
Denominator Exception |
ID: DenominatorException_1
Description: Unavailability of BCG within 6 months after Bladder Cancer Staging Logic Definition: Denominator Exception |
Supplemental Data Guidance | For every patient evaluated by this measure also identify payer, race, ethnicity and sex |
Supplemental Data Elements | |
Supplemental Data Element |
ID: sde-ethnicity
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Ethnicity Logic Definition: SDE Ethnicity |
Supplemental Data Element |
ID: sde-payer
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Payer Logic Definition: SDE Payer |
Supplemental Data Element |
ID: sde-race
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Race Logic Definition: SDE Race |
Supplemental Data Element |
ID: sde-sex
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Sex Logic Definition: SDE Sex |
Measure Logic | |
Primary Library | https://madie.cms.gov/Library/CMS646FHIRIntravesicalBCGTherapy |
Contents |
Population Criteria
Logic Definitions Terminology Dependencies Data Requirements |
Population Criteria | |
Measure Group (Rate) (ID: Group_1) | |
Initial Population | |
|
|
Denominator | |
|
|
Denominator Exclusion | |
|
|
Numerator | |
|
|
Denominator Exception | |
|
|
Logic Definitions | |
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: CMS646FHIRIntravesicalBCGTherapy |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Terminology | |
Code System |
Description: Code system SNOMEDCT
Resource: http://snomed.info/sct Canonical URL: http://snomed.info/sct |
Code System |
Description: Code system ICD10CM
Resource: http://hl7.org/fhir/sid/icd-10-cm Canonical URL: http://hl7.org/fhir/sid/icd-10-cm |
Code System |
Description: Code system ActCode
Resource: http://terminology.hl7.org/CodeSystem/v3-ActCode Canonical URL: http://terminology.hl7.org/CodeSystem/v3-ActCode |
Value Set |
Description: Value set Bacillus Calmette Guerin for Urology Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353 |
Value Set |
Description: Value set Bladder Cancer for Urology Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354 |
Value Set |
Description: Value set Unavailability of Bacillus Calmette Guerin for Urology Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.369 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.369 |
Value Set |
Description: Value set Office Visit
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 |
Value Set |
Description: Value set Payer Type
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Value Set |
Description: Value set Tuberculosis for Urology Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351 |
Value Set |
Description: Value set Immunosuppressive Drugs for Urology Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.364 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.364 |
Value Set |
Description: Value set Cystectomy for Urology Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.358 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.358 |
Value Set |
Description: Value set HIV
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1003 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1003 |
Value Set |
Description: Value set Immunocompromised Conditions
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363 |
Value Set |
Description: Value set Mixed Histology Urothelial Cell Carcinoma for Urology Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365 |
Value Set |
Description: Value set Chemotherapy Agents for Advanced Cancer
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.355 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.355 |
Direct Reference Code |
Display: Male (finding)
Code: 248153007 System: http://snomed.info/sct |
Direct Reference Code |
Display: Female (finding)
Code: 248152002 System: http://snomed.info/sct |
Direct Reference Code |
Display: Tumor staging (tumor staging)
Code: 254292007 System: http://snomed.info/sct |
Direct Reference Code |
Display: American Joint Committee on Cancer cT1 (qualifier value)
Code: 1228889001 System: http://snomed.info/sct |
Direct Reference Code |
Display: American Joint Committee on Cancer cTis (qualifier value)
Code: 1228884006 System: http://snomed.info/sct |
Direct Reference Code |
Display: American Joint Committee on Cancer cTa (qualifier value)
Code: 1228883000 System: http://snomed.info/sct |
Direct Reference Code |
Display: Carcinoma in situ of bladder
Code: D09.0 System: http://hl7.org/fhir/sid/icd-10-cm |
Direct Reference Code |
Display: virtual
Code: VR System: http://terminology.hl7.org/CodeSystem/v3-ActCode |
Direct Reference Code |
Display: Combined radiotherapy (procedure)
Code: 169331000 System: http://snomed.info/sct |
Dependencies | |
Dependency |
Description: QICore model information
Resource: http://hl7.org/fhir/Library/QICore-ModelInfo Canonical URL: http://hl7.org/fhir/Library/QICore-ModelInfo |
Dependency |
Description: Library SDE
Resource: https://madie.cms.gov/Library/SupplementalDataElements|5.1.000 Canonical URL: https://madie.cms.gov/Library/SupplementalDataElements|5.1.000 |
Dependency |
Description: Library FHIRHelpers
Resource: https://madie.cms.gov/Library/FHIRHelpers|4.4.000 Canonical URL: https://madie.cms.gov/Library/FHIRHelpers|4.4.000 |
Dependency |
Description: Library QICoreCommon
Resource: https://madie.cms.gov/Library/QICoreCommon|4.0.000 Canonical URL: https://madie.cms.gov/Library/QICoreCommon|4.0.000 |
Data Requirements | |
Data Requirement |
Type: Patient
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-patient Must Support Elements: extension, birthDate, birthDate.value, url |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1003 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1003 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365 |
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure Must Support Elements: code, performed, status, status.value, id, id.value Code Filter(s): Path: code Code(s): http://snomed.info/sct#254292007: 'Tumor staging (tumor staging)' |
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure Must Support Elements: code, performed, status, status.value, id, id.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.358 |
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure Must Support Elements: code, performed, status, status.value, id, id.value Code Filter(s): Path: code Code(s): http://snomed.info/sct#169331000: 'Combined radiotherapy (procedure)' |
Data Requirement |
Type: MedicationAdministration
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationadministration Must Support Elements: medication, effective, status, status.value Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353 |
Data Requirement |
Type: MedicationAdministration
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationadministration Must Support Elements: medication.reference.value, effective, status, status.value |
Data Requirement |
Type: Medication
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medication Must Support Elements: id.value, code |
Data Requirement |
Type: MedicationAdministration
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationadministrationnotdone Must Support Elements: medication, extension, statusReason Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353 |
Data Requirement |
Type: Observation
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-observation-lab Must Support Elements: value, status, status.value, reference, reference.value |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, class, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 |
Data Requirement |
Type: Coverage
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-coverage Must Support Elements: type, period Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest Must Support Elements: medication, dosageInstruction, status, status.value, intent, intent.value Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.364 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest Must Support Elements: medication, dosageInstruction, status, status.value, intent, intent.value Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.355 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest Must Support Elements: medication.reference.value, dosageInstruction, status, status.value, intent, intent.value |
Generated using version 0.4.8 of the sample-content-ig Liquid templates |